APA (7th ed.) Citation

JM, T., T, O., P, F., C, R., C, P., S, H., . . . E, N. (2026). A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: Toxicity, efficacy, and correlative analysis. Blood advances, 10(4), 1153. https://doi.org/10.1182/bloodadvances.2025016845

Chicago Style (17th ed.) Citation

JM, Tuscano, et al. "A Phase 1 Study of Blinatumomab/lenalidomide in Relapsed/refractory B-cell Lymphoma: Toxicity, Efficacy, and Correlative Analysis." Blood Advances 10, no. 4 (2026): 1153. https://doi.org/10.1182/bloodadvances.2025016845.

MLA (9th ed.) Citation

JM, Tuscano, et al. "A Phase 1 Study of Blinatumomab/lenalidomide in Relapsed/refractory B-cell Lymphoma: Toxicity, Efficacy, and Correlative Analysis." Blood Advances, vol. 10, no. 4, 2026, p. 1153, https://doi.org/10.1182/bloodadvances.2025016845.